Skip to main content

Researchers find a way to create a renewable supply of cancer-fighting T cells

Researchers at the University of California, Los Angeles have made a major advance in the battle against cancer by showing that it’s possible to create mature T cells with important cancer-killing receptors from pluripotent stem cells.

This was achieved by using structures called artificial thymic organoids, which mimic the environment of the thymus, referring to the organ in which T cells develop from blood stem cells.

Related Videos

“Using living T cells to kill cancer cells is one of the most exciting areas of cancer treatment,” Christopher Seet, a clinical instructor in the David Geffen School of Medicine at UCLA, told Digital Trends. “The idea here would be to use self-renewing pluripotent stem cells to make unlimited numbers of T cells in the lab, which could be used directly in patients. With certain tweaks, pluripotent stem cells can be genetically engineered to make T cells that would work in any individual. [This] could make T cell immunotherapies cheaper and more widely available. Currently, T cell therapies use a patient’s own T cells and it takes time and great expense to genetically engineer these T cells and give them back to the patient. In some cases, patients may not qualify if they’re too sick, don’t have enough T cells, or the cell quality is not good enough. Faster and cheaper ‘off-the-shelf’ approaches to T cell therapies are badly needed to bring these treatments to more patients.”

This “off-the-shelf” approach could ultimately work to make T cell therapies more accessible, more affordable, and — perhaps most importantly — more effective. There’s still a way to go until this work rolls out to patients, but it is extremely promising.

“Our next goal is to engineer the pluripotent stem cells to make T cells that are suited for treating any individual,” Seet continued. “To do this we need to make sure that the T cells we make are not rejected by a patient’s immune system, and also specifically attack a patient’s tumor cells and not the rest of their body. We can achieve this by engineering these traits in the stem cells, and indeed our goal is to make T cells that not only can be given to any individual, but may function better than T cells from the blood.”

A paper describing the work was recently published in the journal Cell Stem Cell. Other researchers on the work included Gay Crooks and Amélie Montel-Hagen.

Editors' Recommendations

Groundbreaking stem cell brain implant helps fight epilepsy in rats
epilepsy stem cell brain implant seizures

Severe epilepsy is very difficult to treat, but an experimental approach involving implanted stem cells in the brain represents a groundbreaking way to potentially stop seizures for good.

Carried out by researchers at Texas A&M University, the technique has yet to be tried on human subjects, but has proven highly successful on rats. Rats given the implants suffered 70 percent fewer seizures than those without. That figure could drop further with additional research.

Read more
Chinese search giant Baidu creates an open-source A.I. for detecting cancer
Breast cancer test

Baidu, the Chinese search giant, is sometimes hailed as China’s Google. And just like Google, it has a bunch of innovative side projects which go way beyond straightforward search. We recently covered Baidu’s amazing handheld universal translator. Now the company has announced its latest feat: Using artificial intelligence algorithms to help pathologists better diagnose cancer.

The company has developed an A.I. that is capable of analyzing slides containing biopsied tissue. Reviewing these slides can be difficult, even for experienced pathologists, but Baidu’s deep learning technology is able to look for tiny tumor cells faster and with greater accuracy than previous approaches. In tests, the algorithm was able to outperform both a professional pathologist and the previous winner of the so-called Camelyon16 challenge, a competition intended to evaluate algorithms for automated detection of cancer metastasis in lymph node tissue sections.

Read more
Splinter Cell’s Sam Fisher is sneaking his way into ‘Ghost Recon Wildlands’
splinter cell blacklist review screenshot 8

Tom Clancy's Ghost Recon Wildlands - Special Operation 1: Splinter Cell | Ubisoft [NA]

Ubisoft's Splinter Cell series has been dormant since the release of Splinter Cell Blacklist in 2013, but protagonist Sam Fisher is about to make his way into another Tom Clancy game. As part of Ghost Recon Wildlands' free "Special Operations I" content update, Fisher will be making the trip to Bolivia.

Read more